Rhumbline Advisers, a reputable institutional investor, recently disclosed an increase in its ownership stake in Lantheus Holdings, Inc. (NASDAQ: LNTH) during the first quarter of this year. According to the latest Form 13F filing with the Securities & Exchange Commission, Rhumbline Advisers boosted its position by 1.1%, acquiring an additional 2,457 shares of the medical equipment provider’s stock. As a result, Rhumbline Advisers now holds a total of 217,135 shares in Lantheus Holdings. This stake is valued at approximately $17,927,000.
Lantheus Holdings operates in the healthcare industry and specializes in providing medical equipment solutions. Its stock opened at $67.79 on Thursday and has had a fifty-day moving average price of $79.05 and a two-hundred-day moving average price of $81.73. Over the past twelve months, its share price has ranged from as low as $47.46 to a high of $100.85.
With a market capitalization of approximately $4.64 billion, Lantheus Holdings caters to various segments within the healthcare sector and offers a range of medical equipment products that are essential to patient care.
The company maintains a debt-to-equity ratio of 1.01 which signifies moderate reliance on borrowed funds for operations and growth initiatives. Additionally, it boasts favorable current and quick ratios of 4.88 and 4.55 respectively – indicators that showcase its ability to meet short-term financial obligations promptly.
Investors should note that Lantheus Holdings carries a beta value of 0.65 implying relative stability compared to market fluctuations – an important consideration for risk-averse investors who prioritize consistency over aggressive growth potential when making investment decisions.
While it is worth mentioning that Lantheus Holdings’ price-to-earnings (P/E) ratio stands at 165.34, significantly higher than the industry average, investors should conduct comprehensive analysis and consider other relevant factors before making any investment decisions.
In conclusion, Rhumbline Advisers’ increased stake in Lantheus Holdings is a testament to its confidence in the company’s performance within the medical equipment market. Nevertheless, potential investors would be wise in conducting thorough due diligence and assessing their risk tolerance, taking into account key financial ratios, market conditions, and industry trends before considering an investment in Lantheus Holdings.
[bs_slider_forecast ticker=”LNTH”]
Lantheus Holdings, Inc. Garners Investor Attention and Positive Outlook
In recent news, Lantheus Holdings, Inc. has attracted the attention of several large investors who have bought and sold shares of the company. Vanguard Group Inc., a leading investment management company, increased its stake in Lantheus by 4.4% during the third quarter. With this additional investment, Vanguard now owns over 7 million shares of the medical equipment provider’s stock, amounting to a value of $546 million. Similarly, Alliancebernstein L.P., another prominent investor, raised its position in Lantheus by 18.1% during the fourth quarter and now holds more than 3 million shares valued at $162 million.
State Street Corp and Assenagon Asset Management S.A. also increased their positions in Lantheus during previous quarters, further demonstrating the interest from institutional investors and hedge funds in the company’s stock. These investments indicate a growing confidence in Lantheus and its potential for future growth.
In terms of executive movements within the company, President Paul Blanchfield recently sold 408 shares of Lantheus’ stock on August 21st for an average price of $66.10, resulting in a transaction value of $26,968.80. Following this sale, Blanchfield now directly holds approximately 90,067 shares worth $5.95 million.
CEO Mary Anne Heino also sold some of her holdings on August 11th when she disposed of 10,950 shares at an average price of $68.58 per share, totaling $750,951. After this transaction, Heino’s direct ownership stands at roughly 329,467 shares with a value exceeding $22.5 million.
These insider sales have brought the total number of shares sold by insiders within the last three months to 19,315 with a combined worth of $1.35 million – equivalent to approximately 1.50% ownership stake.
Looking more closely at Lantheus’ financial performance, the company recently reported its earnings results for the quarter ending August 3rd. Lantheus surpassed analysts’ expectations with earnings per share (EPS) of $1.40, beating estimates by $0.17. The company also generated revenue of $321.70 million, surpassing analysts’ projections of $306.48 million.
Lantheus has garnered attention from various analysts in recent months due to its strong performance. StockNews.com initiated coverage on Lantheus and awarded it a “buy” rating in their research report released on August 17th. Additionally, other research firms such as JMP Securities, Truist Financial, Mizuho, and SVB Securities have all raised their price targets for Lantheus stock.
Overall, the consensus rating for Lantheus among these research analysts is “Buy,” with an average price target of $121.83 according to data from Bloomberg.
As we move forward into the future, investors and market observers will be keenly observing Lantheus to see how it continues to attract investment interest while maintaining its positive financial trajectory.
